Cartesian Therapeutics, INC Form 4 insider transactions

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, sold a portion of his shares to cover withholding tax obligations and broker fees related to vesting restricted stock units.

Emily English, Chief Operations Officer of Cartesian Therapeutics, sold a portion of her shares to cover tax obligations related to vesting restricted stock units.

Cartesian Therapeutics CEO, Carsten Brunn, sold a total of 17,271 shares of common stock to cover tax obligations and broker fees related to vesting restricted stock units.

Cartesian Therapeutics' Chief Financial Officer, Blaine Davis, sold a total of 7,989 shares of common stock to cover tax obligations and broker fees related to the vesting of restricted stock units.

Carsten Brunn, CEO of Cartesian Therapeutics, reports the acquisition of restricted stock units and employee stock options.

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, reports acquisition of common stock and employee stock options.

Emily English, Chief Operations Officer of Cartesian Therapeutics, reports the acquisition of restricted stock units and stock options.

Blaine Davis, CFO of Cartesian Therapeutics, reports the acquisition of restricted stock units and stock options.

Director Patrick Zenner reports acquiring common stock and stock options in Cartesian Therapeutics, Inc.

Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, reports acquisition of common stock and stock options.

Director Murat Kalayoglu reports acquisition of common stock and stock options in Cartesian Therapeutics.

Timothy C. Barabe, a director of Cartesian Therapeutics, reported the acquisition of common stock and stock options on January 2, 2025.

Director and 10% owner Timothy Springer reports acquiring shares and stock options in Cartesian Therapeutics.

Director Kemal Malik reports acquisition of common stock and stock options in Cartesian Therapeutics.

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, reports the acquisition of stock and option awards.

Director Michael Singer reports acquiring 2,600 shares of common stock and 7,800 stock options in Cartesian Therapeutics, Inc.

Director Carrie Smith Cox reports acquisition of common stock and stock options in Cartesian Therapeutics.

Director Nishan M DeSilva reports acquisition of common stock and stock options in Cartesian Therapeutics.

Director Michael Singer reported gifting 20,000 shares of Cartesian Therapeutics common stock.

Emily English, SVP, Head of Manufacturing at Cartesian Therapeutics, exercised stock options for 7,650 shares of common stock at $3.30 per share.

Director Timothy Springer reports purchasing additional shares of Cartesian Therapeutics (RNAC) between December 19 and December 23, 2024, increasing his total holdings.

A Cartesian Therapeutics executive, Metin Kurtoglu, exercised stock options and sold shares in multiple transactions over two days.

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, exercised stock options and sold shares of common stock over a three-day period.

Director Michael Singer of Cartesian Therapeutics reported the acquisition and disposal of common stock, including shares held directly, indirectly through trusts, and as custodian for children.

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, exercised stock options for 14,000 shares of common stock at $3.23 per share.

Director Timothy Springer of Cartesian Therapeutics has significantly increased his holdings of company stock through a series of open market purchases.

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, executed multiple transactions involving the exercise of stock options and the sale of common stock.

Cartesian Therapeutics' Chief Medical Officer, Milos Miljkovic, exercised stock options and sold shares on November 14th and 15th, 2024.